Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
03/2003
03/13/2003WO2003000174A3 Compositions and methods for intracellular delivery
03/13/2003WO2002102743A3 DEUTERATED N-SUBSTITUTED AND α-SUBSTITUTED DIPHENYLALKOXY ACETIC ACID AMINO ALKYL ESTERS AND MEDICAMENTS CONTAINING THESE COMPOUNDS
03/13/2003WO2002100404A3 Pyridoxal in combination with serotonin re-uptake inhibitor for the treatment of hot flushes
03/13/2003WO2002100354A3 Pyrrolo[2,3-d]pyrimidine nucleoside analogs
03/13/2003WO2002098416A3 Antineoplastic combinations
03/13/2003WO2002098397A3 Therapeutic compositions for modulating the immune response in a mammal and use thereof
03/13/2003WO2002097050A3 Novel estrogen receptor ligand binding domain variants and novel ligands and pharmaceutical compositions
03/13/2003WO2002096317A3 Method for treating glaucoma vi
03/13/2003WO2002094774A3 Oxcarbazepine dosage forms
03/13/2003WO2002092779A3 Method for enriching tissues in long chain polyunsaturated fatty acids
03/13/2003WO2002089796A3 Methods for selective immunomodulation using pimecrolimus
03/13/2003WO2002089757A3 Use of isoflavones in cosmetic or dermatological preparations
03/13/2003WO2002089743A3 Use of compositions for treating rosacea
03/13/2003WO2002088080A3 Dual inhibitors of pde 7 and pde 4
03/13/2003WO2002087513A3 Fused heterocyclic inhibitors of phosphodiesterase (pde) 7
03/13/2003WO2002080850A3 Bulking agents as satiety agents
03/13/2003WO2002078625A3 Therapeutic combinations for cardiovascular and inflammatory indications
03/13/2003WO2002078622A3 Targeted oxidative therapeutic formulation
03/13/2003WO2002077217A3 Human dual specificity protein phosphatase 7-like protein
03/13/2003WO2002076950A3 Imidiazole derivatives and their use as agonists selective at alpha 2b or 2b/2c adrenergic receptors
03/13/2003WO2002076548A3 Methods and apparatus for treating diseased tissue
03/13/2003WO2002076423A3 Skin care compositions containing a sugar amine
03/13/2003WO2002074726A3 Aniline derivatives useful as phosphodiesterase 4 inhibitors
03/13/2003WO2002074719A8 Inhibitors of plasmepsins
03/13/2003WO2002074343A3 The use of non-digestible polymeric foams to sequester ingested materials, thereby inhibiting their absorption by the body
03/13/2003WO2002074291A3 Compositions useful for the treatment of pathologies responding to the activation of ppar-gamma receptor
03/13/2003WO2002074158A3 Two-phase processing of thermosensitive polymers for use as biomaterials
03/13/2003WO2002072543A3 Rxr activating molecules
03/13/2003WO2002072033A3 Chronotherapeutic dosage forms containing glucocorticosteroid
03/13/2003WO2002069939A3 Taste masked pharmaceutical compositions
03/13/2003WO2002068388A3 Acylated piperidine derivatives as melanocortin-4 receptor agonists
03/13/2003WO2002068015A3 Modular infusion device and method
03/13/2003WO2002067902A3 Modulation of release from dry powder formulations
03/13/2003WO2002066469A3 Novel heterocyclic amide derivatives and their use as dopamine d3 receptor ligands
03/13/2003WO2002066427A3 (+)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane, compositions and uses thereof
03/13/2003WO2002065986A9 Transporters comprising spaced arginine moieties
03/13/2003WO2002058706A3 Combination of an estrogen and an androgen for treating hormonal deficiencies in women undergoing estrogen replacement therapy
03/13/2003WO2002058696A3 The use of substituted azetidinone compounds for the treatment of sitosterolemia
03/13/2003WO2002055078A3 Use of chromanes for treating parkinson's disease
03/13/2003WO2002055062A3 Pharmaceutical tablet comprising paroxetine mesylate
03/13/2003WO2002053519A3 Hydrophobic polyamine analogs and methods for their use
03/13/2003WO2002050019A3 Diamines as modulators of chemokine receptor activity
03/13/2003WO2002048143A3 Antimicrobial 2-pyridones, their compositions and uses
03/13/2003WO2002047662A3 Antibiotic/benzoyl peroxide dispenser
03/13/2003WO2002046191A3 Urea substituted imidazoquinoline ethers
03/13/2003WO2002046188A3 Amido ether substituted imidazoquinolines
03/13/2003WO2002045706A3 The use of polymers for inactivating pathogens
03/13/2003WO2002045703A3 Mixtures or organic compounds for the treatmentof airway diseases
03/13/2003WO2002043763A3 Combination of gaba agonists and aldose reductase inhibitors
03/13/2003WO2002043762A3 Combination of gaba agonists and sorbitol dehydrogenase inhibitors
03/13/2003WO2002042332A3 Truncated cd200
03/13/2003WO2002042319A3 2-substituted estrogens as antiangiogenic agents
03/13/2003WO2002041878A3 Titratable dosage transdermal delivery system
03/13/2003WO2002039990A3 Method for screening anti-proliferative compounds and inhibiting tumor growth
03/13/2003WO2002038140A3 Therapeutic uses for ip3 receptor-mediated calcium channel modulators
03/13/2003WO2002036829A3 Methods of diagnosing, preventing and treating neurological disorders and neuronal injuries
03/13/2003WO2002036554A3 Amidino-urea serotonin receptor ligands and compositions, their pharmaceutical uses, and methods for their snythesis
03/13/2003WO2002036553A3 Substituted alkanoic acids
03/13/2003WO2002034708A3 Aliphatic amino-substituted demethoxylated hypocrellins and their synthesis
03/13/2003WO2002034293A3 Use of citric acid as antimicrobial agent or enhancer or as anticancer agent
03/13/2003WO2002032411A3 Combination of statins and sorbitol dehydrogenase inhibitors
03/13/2003WO2002031511A3 Modulation of ligand binding/enzymatic activity of alpha beta proteins
03/13/2003WO2002030465A3 Compositions that inhibit proliferation of cancer cells
03/13/2003WO2002024194A3 Use of statins (hmg-coa reductase inhibitors) for the preparation of medicament as a novel type of immunomodulator, immunosuppressor and anti-inflammatory agent
03/13/2003WO2002024179A3 Method for reducing toxicity of combined chemotherapies
03/13/2003WO2002024178A3 Method for reducing toxicity of combined chemotherapies
03/13/2003WO2002024177A3 Methods of identifying inhibitory compounds and uses thereof
03/13/2003WO2002023190A3 Methods and products related to low molecular weight heparin
03/13/2003WO2002022113A3 Retinoic acid receptor antagonists as promoters of angiogenesis
03/13/2003WO2002020017A3 Use of ectoin or ectoin derivatives for stabilizing p53
03/13/2003WO2002018909A3 Single riser/single capillary blood viscometer using mass detection or column height detection
03/13/2003WO2002017949A3 Novel functions for dp214
03/13/2003WO2002015893A3 Treatment of wounds
03/13/2003WO2002013866A3 Stimulating neutrophil function to treat inflammatory bowel disease
03/13/2003WO2002013797A3 Therapeutic combination of a cetp inhibitor and atorvastatin
03/13/2003WO2002011750A3 Prevention of beta-amyloid neurotoxicity by blockade of the ubiquitin-proteasome proteolytic pathway
03/13/2003WO2002011708A3 Methods for inducing apolipoprotein e secretion
03/13/2003WO2002008401A3 Elongase genes and uses thereof
03/13/2003WO2002006340A3 Tetraspan protein and uses thereof
03/13/2003WO2002005798A3 Pharmaceutical compositions for treating neurological disorders
03/13/2003WO2002003957A3 Compositions for sustained release of antineoplastic taxanes, and methods of making and using the same
03/13/2003WO2002003684A3 Combination for treating psychoses, comprising an antipsychotic and a muscarinic agonist
03/13/2003WO2002000168A3 Combination hiv therapy including camptothecin
03/13/2003WO2001097848A3 Vitronectin receptor antagonist pharmaceuticals
03/13/2003WO2001082911A3 TREATMENT OF PATHOLOGICAL CONDITIONS INFLUENCED BY THE ACTION OF MATRIX METALLOPROTEINASES (MMPs) USING CLIOQUINOL
03/13/2003WO2001073032A3 Compositions and methods for the therapy and diagnosis of prostate cancer
03/13/2003US20030050620 Combinatorial type controlled release drug delivery device
03/13/2003US20030050502 Specifically compactin, lovastatin and pravastatin, by contacting a solution of the hydroxy acid form of the statins with sodium 2-ethylhexanoate
03/13/2003US20030050495 4'-alkyl,6'-(protected hydroxy),7'-hydroxy-spiro(cyclopropane-1,5'-hexahydroindan-2,3 a(4),7a(1)-triene) compound of given formula, intermediate to illudin analogs of the mushroom Omphalotus illudens
03/13/2003US20030050484 A 1-(4-fluorophenyl)-1,3-dihydroisobenzofuran-5-carbonitrile is alkylated with a compound which may be converted to a dimethylaminopropyl group
03/13/2003US20030050461 Protein for use in the diagnosis, prevention and treatment of metabolic, developmental, nutrient transport and cell proliferation disorders
03/13/2003US20030050454 Oligonucleotide sfor use in the treatment of cancer and viral diseases
03/13/2003US20030050442 62 human secreted proteins
03/13/2003US20030050345 Pharmaceutical composition having enhanced antitumor activity and/or reduced side effects, containing an antitumor agent and an hydroximic acid derivative
03/13/2003US20030050343 Novel potentiating compounds
03/13/2003US20030050342 Administering an effective amount of calcium L-threonate to a subject in need of such prevention or treatment
03/13/2003US20030050340 Includes a quantity of calcium acetate sufficient to bind phosphorous in gastrointestinal tract of the individual
03/13/2003US20030050339 Method of administering lactic acid salts to reduce or prevent exertion-related muscle discomfort
03/13/2003US20030050337 Polymorphic B Form of 3-(cyclopropylmethoxy)-4-[4(methylsulfonyl)phenyl]-5,5- dimethyl-5H-furan-2-one
03/13/2003US20030050335 For prevent and treatment of neurodegenerative disorders such as stroke or Alzheimer's disease
1 ... 5535 5536 5537 5538 5539 5540 5541 5542 5543 5544 5545 5546 5547 5548 5549 5550 5551 5552 5553 5554 5555 ... 7860